120 related articles for article (PubMed ID: 33188936)
1. A Case of Paratubal Serous Borderline Tumor Driven by a Somatic BRAF Mutation in an Adolescent Patient.
Chao A; Huang YL; Lin CY; Chao AS; Lee YS; Wu RC; Lai CH
J Pediatr Adolesc Gynecol; 2021 Apr; 34(2):228-230. PubMed ID: 33188936
[TBL] [Abstract][Full Text] [Related]
2. Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers.
Sadlecki P; Walentowicz P; Bodnar M; Marszalek A; Grabiec M; Walentowicz-Sadlecka M
Tumour Biol; 2017 May; 39(5):1010428317706230. PubMed ID: 28488545
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.
Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R
Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420
[TBL] [Abstract][Full Text] [Related]
4. Paratubal Borderline Malignancy: A Case of a 17-Year-Old Adolescent Female Treated with Laparo-Endoscopic Single-Site Surgery and a Review of the Literature.
Lee S; Ahn KH; Park HT; Hong SC; Lee YJ; Kim IS; Kim T
J Pediatr Adolesc Gynecol; 2016 Feb; 29(1):74-6. PubMed ID: 26026220
[TBL] [Abstract][Full Text] [Related]
5. Germ line and somatic mutations of BRAF V599E in ovarian carcinoma.
Ueda M; Toji E; Noda S
Int J Gynecol Cancer; 2007; 17(4):794-7. PubMed ID: 17309670
[TBL] [Abstract][Full Text] [Related]
6. Borderline papillary serous tumor of the fimbriated end of the fallopian tube with peritoneal implants.
Ondic O; Kalis V; Sima R
J Obstet Gynaecol Res; 2011 Nov; 37(11):1702-5. PubMed ID: 21651651
[TBL] [Abstract][Full Text] [Related]
7. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
Sieben NL; Macropoulos P; Roemen GM; Kolkman-Uljee SM; Jan Fleuren G; Houmadi R; Diss T; Warren B; Al Adnani M; De Goeij AP; Krausz T; Flanagan AM
J Pathol; 2004 Mar; 202(3):336-40. PubMed ID: 14991899
[TBL] [Abstract][Full Text] [Related]
8. Whole exome sequence analysis of serous borderline tumors of the ovary.
Boyd J; Luo B; Peri S; Wirchansky B; Hughes L; Forsythe C; Wu H
Gynecol Oncol; 2013 Sep; 130(3):560-4. PubMed ID: 23774303
[TBL] [Abstract][Full Text] [Related]
9. KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome.
Zuo T; Wong S; Buza N; Hui P
Mod Pathol; 2018 Feb; 31(2):350-357. PubMed ID: 29027536
[TBL] [Abstract][Full Text] [Related]
10. Mutation analysis of papillary tubal hyperplasia associated with ovarian atypical proliferative serous tumor and low-grade serous carcinoma.
Huang WC; Tsai CC; Wei MC; Kuo KT
Am J Obstet Gynecol; 2013 Aug; 209(2):e6-8. PubMed ID: 23711666
[TBL] [Abstract][Full Text] [Related]
11. Paratubal borderline serous tumors.
Seamon LG; Holt CN; Suarez A; Richardson DL; Carlson MJ; O'Malley DM
Gynecol Oncol; 2009 Apr; 113(1):83-5. PubMed ID: 19189870
[TBL] [Abstract][Full Text] [Related]
12. Serous borderline tumours of the ovary.
Kurman RJ; Seidman JD; Shih IM
Histopathology; 2005 Sep; 47(3):310-5. PubMed ID: 16115232
[TBL] [Abstract][Full Text] [Related]
13. Mucosal Proliferations in Completely Examined Fallopian Tubes Accompanying Ovarian Low-grade Serous Tumors: Neoplastic Precursor Lesions or Normal Variants of Benign Mucosa?
Wolsky RJ; Price MA; Zaloudek CJ; Rabban JT
Int J Gynecol Pathol; 2018 May; 37(3):262-274. PubMed ID: 28700429
[TBL] [Abstract][Full Text] [Related]
14. A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes.
Russell SE; McCluggage WG
J Pathol; 2004 Jun; 203(2):617-9. PubMed ID: 15141374
[TBL] [Abstract][Full Text] [Related]
15. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors.
Ho CL; Kurman RJ; Dehari R; Wang TL; Shih IeM
Cancer Res; 2004 Oct; 64(19):6915-8. PubMed ID: 15466181
[TBL] [Abstract][Full Text] [Related]
16. Paratubal borderline serous tumor in a postmenopausal woman: a case report.
Baek J
Pan Afr Med J; 2019; 32():129. PubMed ID: 31223417
[TBL] [Abstract][Full Text] [Related]
17. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
18. Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypes.
Jönsson JM; Johansson I; Dominguez-Valentin M; Kimbung S; Jönsson M; Bonde JH; Kannisto P; Måsbäck A; Malander S; Nilbert M; Hedenfalk I
PLoS One; 2014; 9(9):e107643. PubMed ID: 25226589
[TBL] [Abstract][Full Text] [Related]
19. The molecular pathology of ovarian serous borderline tumors.
Malpica A; Wong KK
Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i16-i19. PubMed ID: 27141064
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges.
Shih IeM; Kurman RJ
Clin Cancer Res; 2005 Oct; 11(20):7273-9. PubMed ID: 16243797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
